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Abstract: The epidermal growth factor (EGF) receptors play an important role in epithelial 
cell function. Upon stimulation of these receptors, an extensive network of signal transduction 
pathways is activated, including the PI3K/AKT and Ras/Erk pathways. This activation leads 
to cellular proliferation and survival. In breast cancer, the EGF receptor, ErbB2 (HER2/neu), 
can be ampliﬁ  ed and over-expressed and this is associated with poor prognosis and drug resis-
tance. Trastuzumab is a monoclonal antibody against ErbB2 and has demonstrated activity in 
the therapy of breast cancer patients with over-expression of ErbB2, both in the metastatic and 
adjuvant setting. Recently, a tyrosine kinase inhibitor, lapatinib, that targets both ErbB1 and 
ErbB2, has also shown activity in metastatic breast cancer. In this review, we will discuss the 
ErbB receptors and their signaling networks in breast cancer, as well as the clinical activities 
of trastuzumab and lapatinib in this disease.
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Introduction
Some of the most important signaling molecules that maintain cell survival and proliferation 
are the growth factor receptors. Epidermal growth factor (EGF) receptors are key regulatory 
factors in promoting both cell survival and proliferation in epithelial cells. EGF receptors 
(ErbB receptor family) transduces speciﬁ  c cellular signals to the cell leading to speciﬁ  c 
cellular responses through their intracellular tyrosine kinase domain (Burgess et al 2003; 
Herbst 2004). In breast cancer, these ErbB receptors are up-regulated, their tyrosine kinase 
activity is increased and their signaling pathways are constitutively activated making inhib-
iting ErbB receptor tyrosine kinase activity an attractive target in this disease (Hynes and 
Lane 2005). The development of antagonists to one of these ErbB receptors, ErbB2, is an 
example of how molecular-targeted therapy is utilized in breast cancer therapy (Nahta and 
Esteva 2007). In this review, we will discuss how ErbB receptors are activated and how using 
ErbB receptor inhibitors are being developed as effective treatments for breast cancer.
EGF family of receptors (Figure 1)
The EGF receptor (ErbB) family consists of four closely related tyrosine kinase trans-
membrane receptors: ErbB1 (EGFR/HER1), ErbB2 (HER2/neu), ErbB3 (HER3), and 
ErbB4 (HER4) that bind to an array of ligands (Normanno et al 2005). These ligands can 
be classiﬁ  ed in two categories, ligands that predominantly bind to only ErbB1 and ligands 
that bind to ErbB3 and/or ErbB4. EGF binds to only ErbB1 whereas other ligands such as 
neuregulin bind to ErbB3 and ErbB4. Upon binding to their corresponding ligands, the ErbB 
receptors form homo- or hetero-dimers. Upon EGF ligation with ErbB1, the receptor either 
homo-dimerizes or hetero-dimerizes with the other three ErbB receptors. ErbB2 fails to bind 
to ErbB receptor ligands, indicating ErbB2 is a coreceptor contributing to the activation of 
the other ErbB receptors through dimerization. ErbB3 has an inactive kinase domain which 
indicates that is also acts as a co-receptor for activation of other ErbB receptor members Biologics: Targets & Therapy 2007:1(3) 230
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(Normanno et al 2005). After dimerization, the tyrosine kinase 
domain in the receptors phosphorylates tyrosine residues in 
the neighboring receptor. This allows recruitment of adaptor 
proteins, such as Grb2, to receptors and the initiation of signal 
transduction pathways. The receptors are then often endocytozed 
and bind to an adaptor protein, c-cbl, that targets ErbB receptors 
for degradation (Muthuswamy et al 1999). Other receptors are 
recycled back to the plasma membrane where they are available 
to bind to other ligands (Burgess et al 2003).
ErbB receptors are expressed in a variety of human tissues 
of epithelial, mesenchymal and neuronal origin. The biologi-
cal function of these receptors has been demonstrated in a 
number of different mouse models. Mice lacking ErbB1 have 
abnormal eyes and epidermal tissues and die due to defects 
in epithelial organ development. In mice lacking ErbB2, a 
malformation of the heart is found and this contributes to 
death of the mice at midgestation. ErbB3 knockout mice die 
from defects in the heart and neural crest, and lack Schwann 
cell precursors (Olayioye et al 2000).
ErbB receptor signaling pathways 
(Figure 2)
Upon ligation, ErbB receptors are activated. The activated 
receptor kinase phosphorylates tyrosine residues on the 
C-terminal tail of the ErbB receptors (Muthuswamy et al 
1999; Belsches-Jablonski et al 2001). These tyrosine phos-
phorylated sites allow the binding of proteins containing the 
Src Homology 2 (SH2) domain. These proteins consist of 
intracellular docking proteins or adaptor proteins, such as 
Grb2 and Shc. Upon binding to the ErbB receptors, these 
protein associate with other proteins leading to the activation 
of serine threonine kinases that phosphorylate serine or threo-
nine residues on other protein kinases and/or transcription 
factors (Olayioye et al 2000). This kinase cascade leads to 
ampliﬁ  cation of a network of signaling pathways resulting in 
changes in protein functions and activation of gene transcrip-
tion. Two of the most prominent signaling pathways found 
after ErbB receptor activation are the Ras/Erk and the PI3K/
AKT pathways. Mitogen activated protein kinases (MAPKs) 
are a superfamily of protein serine-threonine kinases in 
which Erk1/2 are members. ErbB receptors activate Erks 
through the binding of adaptor protein Grb2 to ErbB recep-
tor recruiting son of sevenless (SOS) protein to the receptor 
(Wu et al 1993). SOS is a guanyl nucleotide-release protein 
(GNRP) that upon recruitment to the plasma membrane by 
the activated cell surface receptor causes the small G protein 
RAS to release GDP and exchange it for GTP. When Ras 
has GTP bound to it, it becomes active. Activation of Ras 
ErbB1/ErbB2
ErbB2/ErbB2
ErbB1/ErbB3 ErbB1/ErbB4 ErbB2/ErbB4 ErbB2/ErbB3
ErbB1/ErbB1
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ErbB4/ErbB4
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Figure 1 ErbB receptors form homo- and hetero-dimers upon activation.   The ErbB receptor family consists of ErbB1 (EGFR), ErbB2 (HER2/neu), ErbB3 (HER3), and ErbB4 
(HER4). These receptors form homo- or hetero-dimers upon activation. The only exception is ErbB3 homo-dimer since ErbB3 has a non-functional tyrosine kinase domain. 
ErbB2 homo-dimers occur independent of ligand whereas the other dimers depend on binding of ligands for activation.Biologics: Targets & Therapy 2007:1(3) 231
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leads to the activation of the MKKK Raf-1, Raf-1 kinase then 
phosphorylates and activates the MKK Mek1/2. Activated 
Mek1/2 then phosphorylates and activates Erk1/2 (Johnson 
et al 2005). This increased expression results in phosphoryla-
tion of a variety of substrates including 90 kDa ribosomal S6 
protein kinase (Rsk), Msk1, cytosolic phospholipase A2, and 
transcription factors c-Myc, NF-IL6, Tal-1, Ets-2, and Elk 
(Widmann et al 1999). As a result, there is enhanced gene 
transcription with increased cell survival and proliferation 
(Lin et al 2002).
ErbB receptors also activate the PI3K/AKT pathway 
through recruitment of PI3K to the plasma membrane and 
this is mediated by binding of its SH2 domain to tyrosine 
phosphorylated proteins. PI3K activation catalyzes the trans-
fer of a phosphate group from ATP to phosphatidylinositol 
generating a 3'-phosphatidylinositol phosphate (PIP). PIPs 
act as binding sites for proteins with pleckstrin homology 
(PH) domains. PI3K signaling is negatively regulated by 
PTEN that dephosphorylates PIPs. AKT is a serine/threonine 
kinase that contains a PH domain. AKT’s PH domain binds to 
phosphatidylinositols generated by PI3K translocating AKT 
to the plasma membrane where it becomes phosphorylated 
and activated (Song et al 2005). Activated AKT can either 
activate or inhibit a number of downstream targets that 
participate in cellular survival. AKT activates transcription 
factor NFκB, HIF-1α and CREB resulting in increased tran-
scription of anti-apoptotic genes such as growth factors and 
Bcl-2 family members that prevent cell death. In contrast, 
AKT inactivates transcription factors Foxo (forkhead family) 
and p53, either directly phosphorylating Foxo proteins or by 
phosphorylating and activating Mdm2, a negative regulator 
of p53 (Brunet et al 1999; Zhou et al 2001). In both cases, 
pro-apoptotic gene expression is decreased and cell sur-
vival is increased. AKT also phosphorylates and activates 
mTOR, a serine/threonine kinase. mTOR activation lead to 
phosphorylation and activation of ribosomal S6 kinase and 
the eukaryotic initiation factor 4E (eIF4E) – binding protein 
1 (4E-BP1). This increases the translational capacity within 
Bcl-2
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Figure 2 ErbB receptor signaling. EGF binds to its ErbB receptors leading to activation of a network of signaling pathways, including the PI3K/AKT and RAS/ERK pathways. 
These pathways lead to the activation of anti-apoptotic proteins (white) and the inactivation of pro-apoptotic proteins (black). ErbB2 homodimers activate the same 
pathways but do not require EGF for activation and ErbB receptors can also be activated through tyrosine phosphorylation of the ErbB receptors mediated by non-tyrosine 
kinase Src.Biologics: Targets & Therapy 2007:1(3) 232
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cells and has been implicated in cell survival (Chan 2004; 
Sun et al 2005).
ErbB receptor family and breast 
cancer
ErbB receptor family members were ﬁ  rst implicated in cancer 
in the early 1980s when the avian erythroblastosis tumor virus 
was found to encode an aberrant form of the receptor ErbB1 
(Herbst 2004). Since then, activation of ErbB receptor family 
members has been implicated in the pathogenesis of gliomas 
and lung, head and neck and renal carcinomas. However, it 
is the activation of ErbB receptors in breast cancer that has 
been the focus of the most research and clinical investiga-
tion (Janmaat and Giaccone 2003). In breast cancer, ErbB2 
expression is increased in approximately 25% of tumors, 
as a result of gene ampliﬁ  cation (Normanno et al 2005). 
Since ErbB2 does not require a ligand to become activated, 
increased expression in breast cancer causes increased ErbB2 
signaling through homo- and hetero-dimerization and this 
leads to to increased resistance to cell death (apoptosis), 
increased cell proliferation and enhanced invasiveness. 
Breast cancer patients with with high ErbB2 expression 
generally have aggressive disease and poor prognosis (Nor-
manno et al 2005). In addition, ErbB1 expression is elevated 
in about 30% of breast tumors and is often complexed with 
ErbB2. The ErbB1 gene is rarely mutated in breast cancer but 
in lung cancer and glioblastoma multiforme, the intracellular 
domain of ErbB1 is mutated rendering the tyrosine kinase 
constitutively active (Pedersen et al 2001). These patients 
generally have aggressive disease. The microenvironment 
in breast cancer can also inﬂ  uence ErbB receptor signaling 
as the stromal cells may secrete EGF which then leads to 
activation of the receptors (Normanno et al 2005).
Activation of the Ras/Erk signaling pathway by ErbB is 
deregulated by mutations in Ras that increase Erk signaling 
(Rajagopalan et al 2002; Duursma and Agami 2003). Many 
breast cancers also contain mutations in the tumor suppres-
sor PTEN, that dephosphoryates the second messenger lipid, 
PtdIns (3,4,5) triphosphate, causing down-regulation of the 
PI3K/AKT signaling pathway. In approximately 25% of 
breast tumors, PTEN is mutated and this inhibits its lipid 
phosphatase activity which increases EGF-mediated AKT 
activation and cell survival (Sansal and Sellers 2004). In 
addition, transcription factors are often altered in breast 
cancer. NFκB and CREB transcriptional activation are 
often increased whereas tumor suppressor p53 is mutated in 
many breast cancers (Dolcet et al 2005; Shankar et al 2005; 
Yu and Zhang 2005). As a result, there is an alteration in 
the expression of the pro- and anti-apoptotic proteins. For 
example, anti-apoptotic Bcl-2 family members Bcl-2, Bcl-xL 
and Mcl-1 levels are often elevated in breast cancer and this 
is associated with drug resistance (Kumar et al 1996; Stoll 
et al 1998; Wang et al 1999; Henson et al 2003; Yu and Zhang 
2005). The multi-faceted alterations in the ErbB receptor 
mediated signaling pathways in breast cancer ensure that the 
cells can survive in different environments and contribute 
to tumor progression. As a result, these receptors, especially 
ErbB2, are attractive targets for cancer therapy.
ErbB receptor inhibitors in breast 
cancer therapy (Table 1)
There are two classes of ErbB receptor inhibitors. The 
ﬁ  rst class of inhibitors are monoclonal antibodies which 
are directed against the ErbB receptors and these inhibit 
ErbB signaling and may induce immune mediated cell 
killing. These monoclonals target the over-expression of 
ErbB in breast cancer and the most effective antibody to 
date is trastuzumab (Dassonville et al 2007; Nahta and Esteva 
2007). The second class of inhibitors are tyrosine kinase 
inhibitors that inhibit the tyrosine kinase activity of ErbB 
receptors and thereby inhibit ErbB receptor signaling. The 
most promising tyrosine kinase inhibitor in breast cancer 
treatment is lapatinib that blocks the activation of ErbB1 and 
ErbB2. Lapatinib has similar effects to trastuzumab and may 
be particularly effective when combined with trastuzumab 
(Moy and Goss 2006). The clinical responses for transtu-
zumab and lapatinib in breast cancer are discussed below.
Trastuzumab in breast cancer
Trastuzumab is the first monoclonal antibody targeting 
ErbB2 that has been approved for clinical use. This antibody 
binds to ErbB2, causing receptor endocytosis and/or abla-
tion of ErbB2 signaling, which include the activation of the 
Ras/Erk and PI3K/AKT pathways (Johnston et al 2006). In 
addition, trastuzumab contains a human IgG1Fc region that 
activates antibody-dependent cellular cytotoxicity (ADCC) 
when it binds to ErbB2 (Hynes and Lane 2005). The initial 
clinical trials with trastuzumab in metastatic breast cancer 
over-expressing ErbB2 showed response rates ranging from 
12 to 34% (Baselga et al 1996; Cobleigh et al 1999; Vogel 
et al 2002). Subsequent studies combined trastuzumab with 
paclitaxel or docetaxel in metastatic breast cancer. Response 
rates ranged from 50% to 72%, with the time to progression 
ranging from 7.4 to 9 months, and overall survival from 25 
to 31 months (Seidman et al 2001; Slamon et al 2001; Esteva 
et al 2002). These results were signiﬁ  cantly higher than Biologics: Targets & Therapy 2007:1(3) 233
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when patients were treated with taxenes alone. In addition, 
in patients with metastastic breast cancer with ampliﬁ  cation 
of the ErbB2 gene, there was a median time to progression 
of 4.9 months with trastuzumab mono-therapy compared to 
7.4 months when trastuzumab was combined with chemo-
therapy, such as paclitaxel (Slamon et al 2001). When used in 
the adjuvant setting in breast cancer, trastuzumab was found to 
improve disease-free and overall survival rates when given in 
combination with chemotherapy or following chemotherapy 
(Piccart-Gebhart et al 2005; Romond et al 2005). In one study, 
patients were given doxorubicin/cyclophosphamide followed 
by 12-weekly doses of paclitaxel (group A) while the second 
group (group B) was given doxorubicin/cyclophosphamide 
followed by 52 weeks of trastuzumab and paclitaxel. The 
result was an increase in time to progression in group B 
from 67 months to 87 months and increased overall survival 
group B from 86% to 91% (Romond et al 2005). This led to 
the approval of trastuzumab as a therapy in early stage breast 
cancer patients with elevated ErbB2 expression.
Lapatinib therapy in breast cancer
The second class of ErbB receptor inhibitors are the tyrosine 
kinase inhibitors. This type of inhibitor provides an advan-
tage over monoclonal antibodies as it directly inhibits ErbB 
receptor signaling by blocking the receptor’s kinase activity. 
Tyrosine kinase inhibitors are also taken orally as opposed 
to monoclonal antibodies which need to be administered 
intravenously. This eliminates the need for patients to attend 
the chemotherapy unit for treatments and the risk of allergic 
reactions to the antibody (Moy and Goss 2006).
The ﬁ  rst ErbB tyrosine kinase inhibitors, geﬁ  tinib and erlo-
tinib, were against ErbB1. These inhibitors are effective against 
non-small cell lung cancers that over express ErbB1, and are 
particularly effective against cells expressing a mutation in the 
kinase domain that renders these receptors constitutively active 
(Johnston et al 2006). Lapatinib is a tyrosine kinase inhibitor 
that inhibits the kinase activity of ErbB1 and ErbB2. In preclini-
cal studies, lapatinib inhibited ErbB1 and ErbB2 phosphoryla-
tion in an ErbB2 over-expressing BT474 breast cancer cell line. 
In mouse xenografts, the growth of BT474 tumors was inhibited 
by 94% following treatment with lapatinib. The activation 
of Erk and AKT was also inhibited (Xia et al 2004). These 
results suggest that Erk and/or AKT activation could be a use-
ful biomarker for responsiveness to tyrosine kinase inhibitors. 
Preclinical studies have also demonstrated that lapatinib can 
block growth in breast cancer cell lines. Lapatinib caused 50% 
reduction in kinase activity of ErbB1 and ErbB2 at concentra-
tions less than 0.2 μM in several cell lines and xenograft tumor 
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model (Xia et al 2002). Lapatinib is also effective in breast 
cancer cell lines that are resistant to trastuzumab treatment (Xia 
et al 2004; Zhou et al 2004). There is a signiﬁ  cant correlation 
with response to lapatinib and ErbB2 expression and its ability 
to inhibit Raf, Erk and AKT activation (Konecny et al 2006). 
In murine mammary xenografts of estrogen receptor posi-
tive, tamoxifen resistant tumors, lapatinib restored tamoxifen 
sensitivity. ErbB receptors have been implicated in endocrine 
resistance in breast cancer cells through phosphorylation of 
the estrogen receptor by Erk and AKT signaling pathways 
(Konecny et al 2006). Lapatinib could reverse this resistance 
indicating that combining tamoxifen with lapatinib might be 
a rational and effective treatment. Indeed, a combination of 
lapatinib and tamoxifen produced a greater antiproliferative 
effect in breast cancer cells than either drug alone (Chu et al 
2005). Furthermore, trastuzumab in combination with lapatinib 
showed a synergistic effect on the proliferative capacity of 
several breast cancer cell lines (Konecny et al 2006). Finally, 
through effects on ErbB signaling, lapatinib has been shown 
to sensitize breast cancer cells to irradiation in vitro (Zhou et al 
2004). These preclinical results provide the rationale to develop 
clinical trials in breast cancer using lapatinib in combination 
with other treatment modalities.
A phase I clinical trial on 67 previously treated breast cancer 
patients with overexpression of ErbB1 and ErbB2 and meta-
static disease showed that lapatinib was well tolerated, and side-
effects included diarrhea, rash and fatigue, which are typically 
seen with ErbB targeted therapies. Importantly, none of the 
patients experienced cardiac toxicity (Moy and Goss 2006; Ito 
et al 2007). Phase II clinical trials are ongoing to evaluate lapa-
tinib activity in metastatic breast cancer which is refractory to 
trastuzumab, anthracyclines, taxenes, and capecitabine. Interim 
analysis of one these trials revealed two partial responses and 
17 stable disease (Geyer et al 2006). When lapatinib was used 
alone in trastuzumab naïve breast cancer patients, the response 
rate was 24% and the median time to treatment failure was 
16.1 weeks (Ito et al 2007). In addition, inﬂ  ammatory breast 
cancer patients that were ErbB2 over-expressing showed a 72% 
response to lapatinib alone (Tuma 2007). Lapatinib has also 
been studies in combination with cytotoxic drugs. In a random-
ized phase III trial, 528 patients with ErbB2-expressing breast 
tumors who had been previously been treated with anthracy-
clines, taxenes or trastuzumab received either capecitabine 
alone or capecitabine in combination with lapatinib (Geyer 
et al 2006). Of the 324 patients initially analyzed, the combina-
tion treatment showed a 22% response rate while capecitabine 
alone gave a 14% response rate. The time to progression was 
8.4 months with the combination treatment and 4.4 months 
with capecitabine alone (p   0.001, hazard ratio = 0.47). Of 
note, there was a reduced incidence of metastasatic disease 
to the central nervous system in patients treated with the 
combination treatment and no increase in toxicity (Geyer et al 
2006). This has led the Food and Drug Administration (FDA) 
to approve the use of the lapatinib/capecitabine combination 
in metastatic breast cancer (Engel and Kaklamani 2007). Other 
phase III clinical trials are ongoing comparing lapatinib and 
paclitaxel as ﬁ  rst line therapies for ErbB2 over-expressing 
locally advanced or metastatic breast cancer. The preliminary 
results show that 77% of patients have a clinical response 
and pathological complete response was observed in 17% of 
patients with inﬂ  ammatory breast cancer following lapatinib 
treatment. However, the number of patients are relatively small 
(30 patients treated) (Ito et al 2007).
These results indicate that lapatinib might be as effective 
as trastuzumab in ErbB2-expressing breast cancers and leads 
to the question as to whether combining trastuzumab and 
lapatinib might increase the response rate and survival. In 
support of this concept are the results of preclinical investiga-
tions which indicate that a synergistic antitumor effect is seen 
in ErbB2-positive breast cancer cells treated with a combina-
tion of trastuzumab and lapatinib, and this effect is associated 
with a decrease in the expression of the anti-apoptotic protein, 
survivin (Xia, Bisi et al 2006). A phase I clinical trial using 
lapatinib and weekly trastuzumab has been carried out in 
48 patients breast cancer patients with metastatic disease, 
and one complete response and 5 partial responses have been 
observed in 27 patients (Ito et al 2007).
In the future, lapatinib will be studied in larger phase III 
clinical trials. The adjuvant use of lapatinib for early stage 
ErbB2 over-expressing breast cancer is being conducted in the 
TEACH trial, where patients receive a one year treatment with 
lapatinib or placebo following treatment with an anthracycline 
or taxene containing regimen. Three thousand patients are to 
be recruited to this trial. The ALTO (adjuvant lapatinib and/or 
trastuzumab treatment optimization) phase III trial is under 
development and will involve 8000 patients. ErbB2-expressing 
breast cancer patients will be treated following chemotherapy 
with lapatinib or trastuzumab for one year or a sequence of both 
lapatinib and trastuzumab. These large scale trials will deter-
mine the clinical efﬁ  cacy of lapatinb alone or in combination 
with trastuzumab (Moy and Goss 2006; Ito et al 2007).
Limitations to ErbB receptor 
inhibitor therapy (Figure 3)
Trastuzumab is effective in treating breast cancer patients 
with ampliﬁ  cation of ErbB2. Unfortunately, some patients Biologics: Targets & Therapy 2007:1(3) 236
Henson et al
will not respond to trastuzumab therapy and even in 
trastuzumab responsive patients, its effectiveness is limited. 
One of these limitations is drug resistance, and 15% of early 
stage breast cancer patients with ErbB2 positive tumors 
will not beneﬁ  t from adjuvant trastuzumab and develop 
metastatic disease (Piccart-Gebhart et al 2005; Romond et al 
2005). Therefore, some patients have de novo resistance to 
trastuzumab. Furthermore, patients that initially respond to 
trastuzumab may develop resistance through acquired or 
treatment-induced mechanisms. This is a major limitation 
in the clinical use of trastuzumab. Trastuzumab resistance 
occurs through multiple mechanisms. It has been shown 
that trastuzumab does not prevent dimerization of EGF 
receptors allowing dimers, such as ErbB3/ErbB2, to form. 
In trastuzumab-resistant cells, it has been demonstrated that 
ErbB3/ErbB2 dimers may form and permit constitutive 
signaling to occur (Wehrman et al 2006). Similarly, insulin-
like growth factor one receptor (IGF1R) is tyrosine kinase 
receptor that is over-expressed in breast cancers and binds 
to ErbB2 in trastuzumab-resistant cells (Nahta and Esteva 
2007). This association forms a heterodimer complex that 
leads to increased activation of the PI3K/AKT and Ras/Erk 
signaling pathways and subsequent resistance to cell death 
(Wehrman et al 2006; Ito et al 2007). The most common 
mechanism in trastuzumab resistance is cleavage of the 
ErbB2 extracellular domain leaving the intracellular domain 
intact and capable of signaling. This removes the binding 
site for trastuzumab without affecting ErbB2 signaling (Xia 
et al 2004). These mechanisms of resistance reveal the need 
to develop new targeted therapies that will block or reverse 
trastuzumab resistance in breast cancer patients.
To combat trastuzumab resistance, new ErbB2 targeted 
monoclonal antibodies have been developed. Pertuzumab, 
formerly known as rhuMab-2C4, binds to the extracellular 
domain II of ErbB2 and blocks the interactions between 
ErbB2 and other ErbB receptor family members (Nahta 
et al 2004). In addition, pertuzumab blocks heterdimeriza-
tion of ErbB2 to IGF1R (Nahta et al 2005). This ability to 
block ErbB2 hetero-dimerization holds the promise that 
pertuzumab will overcome trastuzumab resistance in breast 
cancer patients. In a phase I clinical trial, pertuzumab was 
found to be well tolerated and clinically active in 21 breast 
cancer patients with advanced disease. Currently pertuzumab 
is being combined with trastuzumab in phase II clinical 
testing for locally advanced breast cancer with ErbB2 
over-expression (Johnston et al 2006). In xenograft tumor 
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Figure 3 Resistance to trastuzumab in breast cancer.   Trastuzumab inhibits the activation of ErbB2 in ErbB2 over-expressing breast cancer cells (sensitive) but many breast 
cancer patients have or develop resistance to this antibody.   This resistance occurs due to the ability of ErbB2 to hetero-dimerize with ErbB3 or insulin growth factor 1 
receptor (IGF1R). In addition ErbB2 is cleaved or alternatively translated into p95 ErbB2 protein lacking the trastuzumab binding sites. This renders breast cancer cells resis-
tant to trastuzumab treatment. Pertuzumab is a monoclonal antibody that prevents ErbB2 dimerization with other receptors and could overcome trastuzumab resistance. 
Lapatinib inhibits the tyrosine kinase activity in ErbB2 therefore blocks ErbB2 activation when dimerized and in the p95 form.Biologics: Targets & Therapy 2007:1(3) 237
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models of breast cancer, a combination of pertuzumab and 
trastuzumab increased tumor regression (Arpino et al 2007). 
In addition to pertuzumab, preclinical studies have also 
shown that inhibitors of the IGF1R restored sensitivity to 
trastuzumab in trastuzumab-resistant cells by disrupting the 
ErbB2/IGF1R interaction (Jerome et al 2006). In addition, 
IGF1R kinase inhibitors induce apoptosis in trastuzumab 
resistant cell lines (Nahta and Esteva, 2007). However, 
these potential treatments for trastuzumab-resistant patients 
have one major drawback. They will be ineffective against 
breast cancer cells expressing the p95 cleaved form of 
ErbB2. Tyrosine kinase inhibitors such as lapatinib are, 
however, effective at inhibiting that activation of truncated 
forms of ErbB receptor such as p95 ErbB2. In xenograft 
breast tumors expressing p95 ErbB2, lapatinib treatment 
was effective at reducing tumor growth (Xia et al 2004). In 
cell lines selected for long term outgrowth in trastuzumab 
containing media, lapatinib still has activity against ErbB 
receptors (Konecny et al 2006). These results suggest that 
combining trastuzumab with other ErbB2 inhibitors could 
reduce trastuzumab resistance.
The use of trastuzumab is also limited by toxicity. In some 
patients signiﬁ  cant cardiotoxicity is observed although this 
will resolve in 50% of cases after discontinuation of therapy. 
In the adjuvant setting, grade 3 or 4 congestive heart failure 
occurs in 4% of patients but most of the symptoms will resolve 
after therapy is completed. Risk factors for cardiotoxicity 
are age ( 60 years old), concurrent use of anthracyclines 
(known cardiotoxin) and prior irradiation. The reason for 
trastuzumab cardiotoxicity is unclear but mice lacking ErbB2 
expression have cardiac trabeculae dysfunction (Nahta et al 
2007). The most common side effect, however, is skin rash. 
The most common skin eruptions seen are acneform rash. This 
rash is different form typical acne by the absence of blackheads 
or whiteheads and the presence of pruritus (Johnston et al 
2006). This side effect may actually be a good sign, since skin 
epidermal cells have ErbB receptors and the rash indicates that 
the treatment is effecting ErbB-expressing cells (Herbst 2004). 
Finally in some patients, hypersensitivity reactions occur with 
trastuzumab, but these usually occur initially and may not 
reoccur with subsequent injections (Johnston et al 2006).
Similar to trastuzumab, lapatinib might have limitations. 
Some breast cancer patients will fail to respond to lapatinib 
(Geyer et al 2006). It was found in ErbB2 over-expressing 
early-stage breast cancer patients treated with lapatinib that 
their biopsied tumor tissue had increased estrogen recep-
tor signaling, as determined by up-regulation of FOXO3a, 
progesterone receptor (PR) and Bcl-2 (Xia, Bacus et al 
2006). This suggests that lapatinib-resistance could be 
mediated by activation of estrogen receptor signaling. This 
could also cause these tumors to become endocrine sensi-
tive. Indeed, combining lapatinib and tamoxifen increases 
apoptosis in estrogen receptor positive breast cancer cells 
(Chu et al 2005). Lapatinib might also have other clinical 
limitations. These include the ability of ErbB receptors to 
mutate their kinase domain rendering the lapatinib inef-
fective. This was the case for imatinib in chronic myeloid 
leukemia (CML) patients where mutations in the bcr-abl gene 
casued resistance to imatinib (Mughal and Goldman 2007). 
Another concern is the dimerization of ErbB2 with IGF1R 
or ErbB4, where there is tyrosine kinase activity that is not 
inhibited by lapatinib and/or changes in the PI3K/ATK or 
Ras/Erk pathways which are independent of ErbB2 activa-
tion. It remains to be determined what the mechanism(s) of 
lapatinib resistance is in breast cancer patients.
Concluding remarks
ErbB receptors are critical regulators of signaling events 
that can lead to breast cancer progression and are targets for 
cancer therapy. Trastuzumab has shown success in treating 
breast cancer but has limitations including development of 
drug resistance and toxicities. Lapatinib overcomes some of 
these limitations. Lapatinib targets the intracellular kinase 
domain of these receptors making loss of extracellular portion 
of the receptor clinically irrelevant. In addition, lapatinib does 
not cause the cardiotoxicity seen with trastuzumab (Ito et al 
2007). Combining trastuzumab and lapatinib is currently 
under clinical investigation in an attempt to increase efﬁ  cacy 
and minimize toxicity.
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